Compare XPEV & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPEV | WST |
|---|---|---|
| Founded | 2015 | 1923 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 20.1B |
| IPO Year | 2020 | N/A |
| Metric | XPEV | WST |
|---|---|---|
| Price | $20.01 | $279.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $24.90 | ★ $346.78 |
| AVG Volume (30 Days) | ★ 18.2M | 661.6K |
| Earning Date | 11-17-2025 | 10-23-2025 |
| Dividend Yield | N/A | ★ 0.31% |
| EPS Growth | N/A | ★ 0.17 |
| EPS | N/A | ★ 6.75 |
| Revenue | ★ $9,912,782,208.00 | $3,017,900,000.00 |
| Revenue This Year | $99.25 | $7.01 |
| Revenue Next Year | $39.50 | $6.20 |
| P/E Ratio | ★ N/A | $41.51 |
| Revenue Growth | ★ 86.64 | 4.92 |
| 52 Week Low | $11.14 | $187.43 |
| 52 Week High | $28.24 | $348.90 |
| Indicator | XPEV | WST |
|---|---|---|
| Relative Strength Index (RSI) | 42.33 | 55.28 |
| Support Level | $18.55 | $269.08 |
| Resistance Level | $21.99 | $285.54 |
| Average True Range (ATR) | 0.87 | 7.15 |
| MACD | -0.33 | 1.29 |
| Stochastic Oscillator | 26.04 | 82.62 |
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.